Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP"

WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (Nasdaq:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq Global Market under the ticker symbols "COEP" and "COEPW," respectively, today, October 31, 2022.  The Company will continue to focus primarily on the development of innovative cell therapy platforms for patients with cancer.